INmune Bio Inc

INmune Bio, Inc. Is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprograms the immune system to fight cancer and Alzheimer’s disease. Its products include pipeline, INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was founded by Mark Lowdell in September 2015 and is headquartered in Boca Raton, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

INmune Bio reports stable financials, eyes growth in diversified programs

INmune Bio's financials remain stable, with a strategic focus on advancing key programs and achieving upcoming milestones.
The company's strengths lie in efficient trial consolidation, diversification into solid tumors, and patient-centric treatment approaches.
Challenges include operational complexities, FDA holds, and the need for successful international site enrollments.
Opportunities for growth include new program launches, expansion into different therapeutic areas, and exploring combination therapies.

INmune Bio advances Alzheimer's and cancer treatments amidst financial strength

INmune Bio's Q1 2023 performance reflects a focus on advancing treatments for Alzheimer's, cancer, and other diseases, supported by a strong financial position.
While facing challenges such as FDA clinical hold and resource allocation, the company's commitment to innovation and diversification presents growth opportunities.
With upcoming milestones and a promising pipeline, INmune Bio is poised to make significant strides in addressing critical medical needs and expanding its therapeutic reach.

INmune Bio reports Q2 loss, progresses in Alzheimer's and solid tumors

INmune Bio's Q2 2023 earnings call highlighted progress in Alzheimer's and solid tumor treatments, with positive effects observed on gray matter microstructure.
The company's financials showed a net loss but with sufficient cash reserves for operations, while upcoming milestones signal growth potential.
Challenges include managing losses, regulatory progress, and market strategies, but opportunities lie in therapeutic advancements and diversification.

INmune Bio advances Alzheimer's and cancer trials amidst financial challenges

INmune Bio made progress in patient enrollment for Alzheimer's and prostate cancer trials, with a focus on regulatory milestones. Financially, the company reported a net loss but maintains a healthy cash position. Challenges include regulatory hurdles and competition, while opportunities exist in upcoming milestones and market expansion.

INmune Bio advances Alzheimer's and prostate cancer trials amid financial challenges

INmune Bio's Q4 2023 Earnings Call highlighted progress in Alzheimer's and prostate cancer trials, with positive regulatory developments. Financially, the company reported a net loss but maintains a healthy cash position. Analyst questions focused on trial specifics and market comparisons.

INmune Bio Inc advances Alzheimer's trials and secures funding for growth

INmune Bio Inc's Q2 2024 showcased progress in Alzheimer's trials, successful fundraising, and strategic milestones ahead
The company's leadership, financial stability, and upcoming trials position it well for growth and market recognition
While facing competitive challenges and operational complexities, INmune Bio Inc remains focused on innovation and market expansion

INmune Bio excels in clinical trials, secures funding for growth

INmune Bio's Q3 2024 earnings call highlighted strong clinical progress, financial growth, and a focus on data-driven decision-making for future success.
The company's emphasis on quality standards, innovative drug delivery, and promising trial results positions them well for upcoming milestones and market impact.
While facing inquiries and challenges, INmune Bio remains confident in its programs, signaling a resilient approach to addressing industry complexities and driving growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Data suggests in triple negative breast cancer that MUC4 predicts survival and resistance to immunotherapy and that INB03 reverses resistance by decreasing immunosuppression in the TME

INmune Bio, Inc. Announces Key Breast Cancer Treatment Resistance Data to be Presented at the 2021 San Antonio Breast Cancer Symposium

Boca Raton, Florida, Dec. 01, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announced two poster presentations at the 2021 British Society of Immunology Congress, which was held November 28-December 1, in Edinburgh, UK.

INmune Bio, Inc. Announces Two Presentations at the 2021 British Society of Immunology Congress and Provides 119-day data on First patient in MDS trial.

INmune Bio, Inc. (INMB) CEO R. J. Tesi on Q3 2021 Results - Earnings Call Transcript

Announces second Phase 2 trial of XPro in Mild Cognitive Impairment (MCI) in addition to previously announced Phase 2 trial in mild Alzheimer's disease (AD)

INmune Bio, Inc. Announces Third Quarter 2021 Results and Provides Business Update

Boca Raton, Florida, Oct. 27, 2021 (GLOBE NEWSWIRE) --   INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announced multiple poster presentations and a plenary talk at the upcoming 14th Clinical Trials on Alzheimer's Disease (CTAD) Annual Meeting, being held in a hybrid format (in-person and virtual) from November 9-12 in Boston.

INmune Bio, Inc. Announces Multiple Oral and Poster Presentations at the 14th Clinical Trials on Alzheimer's Disease (CTAD) Annual Meeting

Management to host conference call and webcast at 4:30 pm ET on that day Management to host conference call and webcast at 4:30 pm ET on that day

INmune Bio, Inc. to Report Third Quarter 2021 Financial Results and Provide a Corporate Update on Wednesday, November 3

GameStop stock continues to defy the Street logic. Its fans are willing to stick around with Ryan Cohen & Co. for the long term. Matt Furlong & the team did not announce anything substantial on its restructuring plans in the recent earnings. But, it did not matter to GameStop fans.

INmune Bio A No-Brainer Investment

Boca Raton, FL, Sept. 27, 2021 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announced that Mark Lowdell, PhD, Chief Scientific Officer and Chief Medical Officer, will be participating in an oncology panel at the B. Riley Fall 2021 Best Ideas in Oncology Series.

INmune Bio, Inc. to Participate in the B. Riley Fall 2021 Best Ideas in Oncology Series

BOCA RATON, Florida, Sept. 20, 2021 (GLOBE NEWSWIRE) --   INmune Bio, Inc.  (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announced that Raymond J. Tesi, MD, President and CEO, is scheduled to participate in two upcoming investor conferences in September 2021.

INmune Bio, Inc. Announces Participation at Upcoming Investor Conferences

INmune Bio (INMB) announces positive data for its AD candidate, XPro, from an early stage study. Shares are up in pre-market.

INmune (INMB) Announces Positive Data for its AD Candidate

The stock price of INmune Bio Inc (NASDAQ: INMB) increased by over 30% this week. This is why it happened.

INMB Stock: Explanation For Over 30% Increase This Week

INmune Bio, Inc. (NASDAQ: INMB) shares traded higher Wednesday afternoon following data out of a trial for the company's Alzheimer's drug candidate. The company said its selective dominant-negative tumor necrosis factor inhibitor candidate for the treatment of Alzheimer's disease, XPro (pegipanermin), was found to decrease multiple species of Phospho Tau and improve neuroimaging biomarkers of myelination in patients with Alzheimer's.

Why Are Shares Of INmune Bio Trading Higher Wednesday Afternoon?

XPro™ treatment shows statistically significant decrease in Phospho Tau 217 (pT271) and pT181, and an improvement in an imaging biomarker of myelination. XPro™ treatment shows statistically significant decrease in Phospho Tau 217 (pT271) and pT181, and an improvement in an imaging biomarker of myelination.

Alzheimer's Patients Treated with INmune Bio's XPro™ Show Reduction in CSF Phospho-Tau and Evidence of Remyelination

INmune Bio Inc (NASDAQ: INMB) announced that the first patient who received INKmune has successfully shown NK activation and functional differentiation. INKmune is a potential candidate for high-risk myelodysplastic syndrome (MDS).

INmune Bio Stock Jumps On Promising Biomarker Data From Early-Stage Blood Cancer Trial

First positive clinical confirmation of in vivo NK response, mirroring in vitro data

INmune Bio, Inc. Announces Biomarker Data Demonstrating that the First Patient Treated with its NK Cell Priming “Pseudokine”, INKmune™, Successfully Produced Memory-Like NK Cells

An in-depth look at the INmune Bio drug pipeline shows that INmune Bio has a diverse set of fields it can target. Potential value comparisons of other companies with similar drugs and catalysts from those drugs show a large upset for INmune Bio.

Our Bullish Take On INmune Bio's Drug Pipeline

BOCA RATON, Florida, Aug. 10, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc.  (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announced that Raymond J. Tesi, MD, President and CEO, will present at the Canaccord Genuity 41st Annual Growth Conference being held August 10 – 12.

INmune Bio, Inc. to Present at the Canaccord Genuity 41st Annual Growth Conference

INmune Bio, Inc. (INMB) CEO David Moss on Q2 2021 Results - Earnings Call Transcript

LA JOLLA, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) --   INmune Bio, Inc.  (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announced that Raymond J. Tesi, MD, President and CEO, will present at the BTIG Virtual Biotechnology Conference being held August 9 – 10.

INmune Bio, Inc. to Present at the BTIG Virtual Biotechnology Conference

Company to host conference call today, August 4, at 4:30pm ET Company to host conference call today, August 4, at 4:30pm ET

INmune Bio, Inc. Announces Second Quarter 2021 Results and Provides Business Update

Management to host conference call at 4:30 pm E T on that day

INmune Bio, Inc. to Report Second Quarter 2021 Financial Results and Provide a Corporate Update on Wednesday, August 4

Phase 2 study of XPro TM will be a six -month , blinded , randomized , placebo-controlled trial in 168 patients with m ild A lzheimer's disease and biomarkers of inflammation .

INmune Bio, Inc. Announces Design of Upcoming Phase 2 Alzheimer's Disease Clinical Trial and New Phase 1b AD Biomarker Data

AMSTERDAM, July 22, 2021 /PRNewswire/ -- LUMICKS, a leading next generation life science tools company renowned for its innovative platforms for Dynamic Single-Molecule and Cell Avidity analysis, has installed its ground-breaking z-Movi® Cell Avidity Analyzer at INmune Bio (NASDAQ: INMB). INmune Bio is a clinical stage biotechnology company developing new therapies that modulate the innate immune system to treat cancer and neurodegenerative diseases, such as Alzheimer's.

INmune Bio acquires LUMICKS' z-Movi® Cell Avidity Analyzer to accelerate the development of its NK cell platform for cancer treatments

Company to introduce design of upcoming Phase 2 study of XPro1595 in Alzheimer's disease, which is expected to commence this year

INmune Bio, Inc. Announces Poster Presentation and Plenary Talk at the Alzheimer's Association International Conference 2021

INmune Bio Inc (NASDAQ: INMB) has announced a direct offering of 1.8 million shares at $22.00 per share for gross proceeds of approximately $40 million. The offering will close by July 16.

News for INmune Bio Inc Stock (INMB)